Avenue Therapeutics (ATXI) Announces Pricing of $5.0 Million Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- S&P 500, Nasdaq rise as tech, chipmakers rebound
- Oil prices settle $1 higher after Iran and Israel say they have halted attacks
- Tech stocks gain as Trump mulls government stake in AI companies
- Morgan Stanley’s Wilson calls Friday U.S. selloff a "healthy reset"
- Hedge funds loaded up on equities ahead of sharp Friday drop
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Salesforce to acquire metering platform M3TER for consumption billing
- Quantum Space to go public via $1.2B SPAC merger
- SpaceX sets $135 price for blockbuster IPO, upending Wall Street convention
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
October 31, 2023 9:15 AM EDTMIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (Avenue or the Company), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the pricing of its public offering of an aggregate of 16,633,400 units at a public offering price of $0.3006 per unit. Each unit consists of (i) one share of common stock (or one pre-funded warrant in lieu thereof), (ii) one Series A warrant to purchase one share of common stock, immediately exercisable at a price of $0.3006 per share and... More
